SignaBlok, Inc. is a biopharmaceutical company developing a new class of therapies â innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. Designated SCHOOL - signaling chain homo-oligomerization - the system is a method of silencing intracellular communication, This novel model of cell signaling - SCHOOL - uncovers the mechanisms of signaling by membrane receptors, a biological process that plays an important role in health and disease; a discovery that potentially opens new avenues for drug development with applications in many serious diseases. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy
